Evolus, Inc. (NASDAQ:EOLS) Q2 2022 Earnings Conference Call August 1, 2022 9:00 AM ET
Company Participants
David Erickson - Vice President, Investor Relations
David Moatazedi - President and Chief Executive Officer
Rui Avelar - Chief Medical Officer and Head of Research and Development
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Annabel Samimy - Stifel
Marc Goodman - SVB
Greg Fraser - Truist Securities
Serge Belanger - Needham and Company
Douglas Tsao - H.C. Wainwright
Uy Ear - Mizuho
Operator
Greetings. Welcome to the Evolus Second Quarter 2022 Earnings Call. At this time, our participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I would now like to turn the conference over to your host, David Erickson, Vice President of Investor Relations. You may begin.
David Erickson
Thank you, operator and welcome to everyone joining us on today's call. With me today are David Moatazedi, President and Chief Executive Officer; and Rui Avelar, Chief Medical Officer and Head of R&D.
Our prepared remarks today will include forward-looking statements within the meaning of United States securities laws, and management may make additional forward-looking statements in response to your questions. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the company's business, strategy, operations or financial performance. A detailed discussion of the risks and uncertainties that the company faces is contained in its annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
Actual results may differ materially from those expressed in or implied by the forward-looking statements. The company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Additionally, today's discussion will include non-GAAP financial measures, which should be considered in addition to and not as a substitute for or in isolation from our GAAP results. A reconciliation of GAAP to non-GAAP results may be found in our earnings release, which was furnished with our Form 8-K filed today with the SEC and on our Investor Relations website at evolus.com. Lastly, following the conclusion of today's call, a replay will be available on our website at evolus.com.
And with that, I'll turn the call over to David.
David Moatazedi
We are pleased to share with you our results for the second quarter of 2022, which reflected above market growth, increased market share and disciplined operating expense management.